Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron(R) in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025
(NASDAQ:DWTX), ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid, Nav 1.7 inhibitor treatments for chronic and acute pain, announced today that dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP (Halneuron(R) Treatment of […]